Trials / Completed
CompletedNCT03036943
Fluciclovine (18F) Imaging of Breast Cancer
An Open-labelled Study to Characterise Fluciclovine (18F) Uptake Measured by positRon emissiON Tomography In Breast cancER
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University of Oxford · Academic / Other
- Sex
- Female
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what a new amino acid-based PET agent, fluciclovine (18F), can tell us about breast cancer biology (how it grows and develops), and quantify the differences in fluciclovine (18F) uptake between breast cancer subtypes. This will inform further work to investigate its use in breast cancer management.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Fluciclovine | Fluciclovine (18F) PET/CT scan completed \>= 48 hours prior to surgical resection for breast cancer |
Timeline
- Start date
- 2017-02-15
- Primary completion
- 2018-12-04
- Completion
- 2018-12-04
- First posted
- 2017-01-31
- Last updated
- 2018-12-19
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03036943. Inclusion in this directory is not an endorsement.